Percutaneous Gelled Alcohol Sclerotherapy for Aggressive Angiomas: Evaluation of Feasibility, Safety, and Efficacy

Recruiting

• Conditions: Bone Angioma

• Registration Number: NCT06607731
• Lead Sponsor: Centre Hospitalier Universitaire de Saint Etienne

Brief Summary

The investigators aimed to evaluate efficacy and safety of a non-surgical protocol treatment combining transarterial embolization and percutaneous radiopaque gelled ethanol (RGE) sclerotherapy in a first procedure, then followed by vertebroplasty in a second procedure, to treat aggressive vertebral hemangioma patients in tertiary hospital. Exclusion criteria were age \<18-years old and any association with neurological deficit.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-06-25
• Study First Submitted: 2024-07-26
• Study First Submitted QC: 2024-09-19
• Study First Posted: 2024-09-23
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-07
• Last Update Posted: 2024-10-08
• Primary Completion: 2024-12
• Study Completion: 2024-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

• Every patients treated by gelled alcohol sclerotherapy for aggressive angiomas, in the University Hospital of Saint-Etienne.

Exclusion Criteria

• Patients no treated by gelled alcohol sclerotherapy.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of complications identified in data collection	Day 1	Number of complications identified in data collection

Secondary Outcome Measures

Name	Time	Method
Number of lesion identified in data collection	Day 1	Number of lesion identified in data collection

Trial Locations

Locations (1)

CHU de Saint-Etienne; 🇫🇷 Saint-Priest-en-Jarez, France